Monitor the Q3 2026 earnings call on November 3, 2026, for updated full-year guidance reflecting the divestiture and any details on debt paydown plans. The pro forma financials due by October 13, 2026, will clarify the revenue and earnings profile of the remaining business.
Price Chart
Executive Summary
Clarivate completed the sale of its Life Sciences & Healthcare segment to Altaris for total consideration of $600 million ($500M cash at close, $75M unsecured senior note, and up to $25M deferred consideration). The company is now a more focused entity centered on its Academia & Government and Intellectual Property segments. Proceeds are intended for debt reduction and balance sheet strengthening. Concurrently, Henry Levy, President of Life Sciences & Healthcare, terminated employment in connection with the transaction.
Key Facts
- Sale of Life Sciences & Healthcare segment to Altaris closed on October 6, 2026.
- Total consideration of $600 million: $500M cash at close, $75M unsecured senior note, up to $25M deferred consideration payable by January 31, 2028.
- Proceeds to be used for debt reduction and balance sheet strengthening.
- Henry Levy, President of Life Sciences & Healthcare, terminated employment upon closing per a previously disclosed retention agreement.
- Company will report Q3 2026 results on November 3, 2026, and update full-year guidance to reflect the divestiture.
- Remaining segments: Academia & Government (Web of Science, ProQuest, Alma, Vega) and Intellectual Property (IPOne, Derwent, CompuMark, IPfolio).
Financial Impact
Total consideration of $600 million, consisting of $500M cash, $75M unsecured senior note, and up to $25M deferred consideration. Proceeds intended for debt reduction.
Risk Factors
- Revenue base will shrink significantly post-divestiture; growth trajectory of remaining segments is unproven at this scale.
- Deferred consideration of $25M is contingent on transition services completion and not guaranteed until January 31, 2028.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001764046-26-000117 |
| Exhibit: ex991pressrelease-janusclo.htm | 0001764046-26-000117 |
| Document: 0001764046-26-000117-index-headers.html | 0001764046-26-000117 |
| Document: 0001764046-26-000117-index.html | 0001764046-26-000117 |
| Document: 0001764046-26-000117.txt | 0001764046-26-000117 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K/A | $1.61 | awaiting T+20 | — | $1.79 (+11.49%) |
Oct 6, 2026 20d ago | 8-K | $1.47 | awaiting T+20 | — | $1.79 (+22.11%) |
Sep 24, 2026 4w ago | 8-K | $1.84 $1.85 | ▲ +0.54% | ▲ +0.96% | $1.79 (−2.45%) |
Sep 22, 2026 5w ago | Press Release | $1.89 $1.78 | ▼ −5.82% | ▼ −5.26% | $1.79 (−5.03%) |
Sep 17, 2026 5w ago | Press Release | $1.90 $1.74 | ▼ −8.42% | ▼ −9.88% | $1.79 (−5.53%) |
Aug 10, 2026 11w ago | Insider Cluster | $1.91 $1.91 | · 0.00% | ▲ +1.06% | $1.79 (−6.02%) |
Aug 3, 2026 12w ago | 144 | $1.97 $2.04 | ▼ −3.55% | ▼ −4.79% | $1.79 (+8.88%) |
Jul 6, 2026 16w ago | 8-K | $2.51 $1.94 | ▼ −22.71% | ▼ −24.04% | $1.79 (−28.49%) |
Jul 6, 2026 16w ago | 8-K | $2.44 $1.98 | ▼ −18.85% | ▼ −18.29% | $1.79 (−26.43%) |
Jun 8, 2026 20w ago | 8-K | $2.38 $2.51 | ▲ +5.46% | ▲ +4.02% | $1.79 (−24.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers